COVID-19 Vaccination for Patients with Parkinson’s Disease Recommended

Experts writing in the Journal of Parkinson’s Disease stress the benefits, efficacy and safety profile of the COVID-19 vaccines for this specific patient population

February 3, 2021 - Amsterdam, NL – Patients with Parkinson’s disease (PD) and healthcare professionals caring for them have expressed concerns about the COVID-19 vaccine’s efficacy and safety in the specific context of PD and its symptomatic treatment. In a commentary just published in the Journal of Parkinson’s Disease, a set of experts addresses these concerns from an evidence-based perspective. Their conclusion is that COVID-19 vaccination with approved vaccines should be recommended to persons with PD, unless there is a specific contraindication. More...

February 3, 2021

Neuromuscular Disease Registry Helps Patients Access Research, Clinical Trials, New Genetic Tests, and Therapies

With data on more than 4,000 patients, the Canadian Neuromuscular Disease Registry celebrates a decade of facilitating research across Canada, reports JND

February 2, 2021 - Amsterdam, NL– The Canadian Neuromuscular Disease Registry (CNDR) was launched in 2010 to increase efficient patient access to cutting-edge research and clinical trials, to increase understanding of the natural history and epidemiology of neuromuscular disease across Canada, and to facilitate research collaboration. An assessment of CNDR’s accomplishments, published in the Journal of Neuromuscular Diseases, found that it has been successful in securing funding and engaging the community over the past 10 years. With more than 4,000 enrolled patients, data from the registry have been used in over 125 research projects as of 2019, including clinical trial and research notifications, patient questionnaires, and data analyses around patient outcomes and care. More...

February 2, 2021

Over Half of Cannabis Users with Parkinson’s Disease Report Clinical Benefits

A survey in Germany found over 8% of patients with Parkinson’s disease are using cannabis products and more than half experienced beneficial clinical effects, reports JPD

January 26, 2021 - Amsterdam, NL – With medicinal cannabis now legalized in many parts of the world, there is growing interest in its use to alleviate symptoms of many illnesses including Parkinson’s disease (PD). According to results of a survey of PD patients in Germany in the Journal of Parkinson’s Disease, over 8% of patients with PD reported using cannabis products and more than half of those users (54%) reported a beneficial clinical effect. More...

January 26, 2021

Study Suggests That Gut Fungi Are Not Associated With Parkinson’s Disease

Although the bacterial microbiome is strongly connected to PD and gut dysfunction is nearly universal in this disease, researchers found that the fungal microbiome does not also play a role, reports the Journal of Parkinson’s Disease

January 21, 2021 - Amsterdam, NL – The bacterial gut microbiome is strongly associated with Parkinson’s disease (PD), but no studies had previously investigated the role of fungi in the gut. In this novel study published in the Journal of Parkinson’s Disease, a team of investigators at the University of British Columbia examined whether the fungal constituents of the gut microbiome are associated with PD. Their research indicated that gut fungi are not a contributing factor, thereby refuting the need for any potential anti-fungal treatments of the gut in PD patients. More...

January 21, 2021